The drug is already approved in several countries for treatment of kidney and liver cancer, and it may be time to consider it for patients suffering from advanced portal hypertension, the authors suggest.
Their findings are in the April issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD). The article is also available online at Wiley Interscience (www.interscience.wiley.com).
Portal hypertension is the most significant complication for patients with liver cirrhosis. It can become serious and life-threatening, and we do not have many effective ways to treat it. Researchers have considered antiangiogenic drugs, which inhibit the growth of new blood vessels, since such vascular formation is a hallmark of portal hypertension, as they have previously demonstrated. One such drug is sorafenib, a powerful multikinase inhibitor that can be taken orally.
Researchers, led by Mercedes Fernandez from the Institute of Biomedical Research IDIBAPS of Barcelona, examined the effects of sorafenib on rats with portal hypertension induced by partial portal vein ligation or bile duct ligation.
“Our present study is the first to determine if the multiple kinase inhibitor sorafenib causes beneficial effects on the splanchnic, intrahepatic and systemic circulations, and on portosystemic collateral vessels in two different experimental models of portal hypertension,” they report.
The rats in the study took sorafenib orally every day for two weeks. They showed no signs of toxicity or adverse effects and the researchers noted numerous improvements in their condition. They had an 80 percent decrease in the growth of new blood vessels and marked lessening of circulation in the areas around the liver. The treatment also decreased portal pressure by 25 percent, and liver fibrosis and inflammation improved.
“Taking into account the limitations of translating animal study results into humans, we believe that our findings will be stimulating for consideration of sorafenib as an effective therapeutic agent in patients suffering from advanced portal hypertension,” the authors conclude.
An accompanying editorial by Vijay Shah of the Mayo Clinic and Jordi Bruix of Barcelona notes the promise of the findings by Mejias and colleagues. “It is obvious that a new avenue for pharmacologic intervention in patients with cirrhosis has emerged,” they write.
They encourage the evaluation of antiangiogenesis therapy in patients with cirrhosis and portal hypertension, though saying it “will need a very careful approach.” Researchers will have to determine the optimal dosage that maintains efficacy while remaining tolerable and safe for patients. They must also consider the impact on cardiac function.
“The challenge is there and it is time to move ahead,” Shah and Bruix conclude.
Article: “Beneficial Effects of Sorafenib on Splanchnic, Intrahepatic and Portocollateral Circulations in Portal Hypertensive and Cirrhotic Rats.” Mejias, Marc; Garcia-Pras, Ester; Tiani, Carolina; Miquel, Rosa; Bosch, Jaime; Fernandez, Mercedes. Hepatology; April 2009.
Editorial: “Antiangiogenic Therapy: Not Just for Cancer Anymore.” Shah, Vijay; Bruix, Jordi. Hepatology; April 2009.
Further reports about: > Hepatology > Sorafenib > antiangiogenic drugs > blood vessel > hypertension > intrahepatic circulations > liver cancer > liver cirrhosis > medication > multikinase inhibitor > portal hypertension > portosystemic collateral vessels > splanchnic circulations > therapeutic agent > treatment of kidney > vascular formation
Staphylococcus aureus: A new mechanism involved in virulence and antibiotic resistance
23.03.2018 | Institut Pasteur
Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy